Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2023-09-28 Earnings Release
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Interim results update and business update
Earnings Release Classification · 95% confidence The document is an 'Interim results update and business update' released by Shield Therapeutics plc. It contains key financial highlights (H1 2023 revenue, prescription growth, KPI performance) and operational updates. While it discusses interim results, it is structured as a press release announcement (RNS) rather than a full, formal interim financial report. It provides a summary of performance and business outlook, fitting the definition of an Earnings Release (ER) as it serves as the initial announcement of period results. H1 2023
2023-09-28 English
Notice of Results and Change in reporting currency
Report Publication Announcement Classification · 99% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) from Shield Therapeutics PLC. The primary content is a 'Notice of interim results' stating *when* the results for the six months ended 30 June 2023 will be announced (September 28, 2023), and it also announces a change in reporting currency. Since this document is not the actual interim financial report itself (which would be an 'IR' or 'ER'), but rather an announcement *about* the upcoming release of results and related investor events (like the Investor presentation), it fits the definition of a Report Publication Announcement (RPA). It is a short notice detailing the publication schedule of a future report.
2023-09-06 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is clearly identified by the header 'RNS Number : 9974G' and contains the standard format for a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership (crossing thresholds). This specific filing reports that Jupiter Fund Management PLC acquired/disposed of voting rights, resulting in a holding of 4.78%. This type of notification falls under regulatory reporting concerning major shareholdings, which corresponds to the 'Major Shareholding Notification' definition (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-07-24 English
Business Update and U.S. Q2 2023 Highlights
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and contains a date (20 July 2023) and a title 'Business Update and U.S. Q2 2023 Highlights'. It provides key performance indicators (KPIs) and financial updates for a specific period (Q2 2023 and 1H 2023) but is not a comprehensive annual report (10-K) or a full interim report (IR). It is a concise announcement of recent operational and financial performance highlights, which aligns best with the definition of an Earnings Release (ER). The presence of the RNS footer confirms it is a regulatory announcement, but ER is more specific than the general RNS code.
2023-07-20 English
Results of 2023 Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly states it announces the "Results of 2023 Annual General Meeting". It details that resolutions 1 through 12 were voted upon, providing a table with FOR, AGAINST, and WITHHELD votes for each resolution. This content directly relates to the outcomes of a shareholder meeting, which aligns perfectly with the definition of AGM Information (AGM-R). Although it is a regulatory announcement format (RNS Number is present), the core subject matter is the AGM results, making AGM-R the most specific classification.
2023-06-28 English
Shield Therapeutics plc Annual Report and Accounts 2022
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual report and accounts 2022' for Shield Therapeutics plc. It contains comprehensive sections including a strategic report, financial highlights, corporate governance, and full audited financial statements (profit and loss, balance sheets, cash flows, and notes). It is a full-year statutory report, not an announcement or a summary. FY 2022
2023-06-12 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.